Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IDH1 | O75874 | 4/20 | 0.41 |
| ▸ | BACE1 | P56817 | 7/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 1/20 | 0.34 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.34 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.34 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.34 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.34 |
| ▸ | FEN1 | P39748 | 1/20 | 0.33 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.33 |
| ▸ | MPO | P05164 | 2/20 | 0.33 |
| ▸ | PAX8 | Q06710 | 1/20 | 0.33 |
| ▸ | PDE4A | P27815 | 1/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.33 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3519485 | 0.92 | IDH1 (0.40) | IDH1BACE1CYP17A1CYP3A4CYP19A1 | |
| SCHEMBL3515013 | 0.91 | IDH1 (0.41) | IDH1BACE1FEN1 | |
| SCHEMBL3519281 | 0.89 | IDH1 (0.40) | IDH1BACE1FEN1HDAC3PAX8 | |
| SCHEMBL18314572 | 0.88 | IDH1 (0.39) | IDH1HDAC3PAX8 | |
| SCHEMBL20278682 | 0.86 | IDH1 (0.41) | IDH1BACE1FEN1 | |
| SCHEMBL3514555 | 0.84 | ADRB2 (0.39) | IDH1FEN1HDAC3PAX8 | |
| SCHEMBL3514404 | 0.77 | CYP3A4 (0.38) | IDH1CYP17A1CYP3A4CYP19A1CYP11B1 | |
| SCHEMBL19509157 | 0.76 | HDAC3 (0.39) | IDH1CYP3A4FEN1HDAC3PAX8 | |
| Bromide SCHEMBL20563813 | 0.75 | HDAC3 (0.38) | CYP3A4FEN1HDAC3PAX8PDE4A | |
| SCHEMBL3514716 | 0.74 | PRMT5 (0.39) | IDH1FEN1PDE4D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | MERCK SHARP & DOHME CORP. | 2010-03-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100056516-A1 | 1-HYDROXY NAPHTHYRIDINE COMPOUNDS AS ANTI-HIV AGENTS | RNASEH1, RNASE1, RNASEL | IDH1 963/4885BACE1 170/4885CYP17A1 891/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.